CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Advantages of Using Monoclonal Antibodies

Advantages of Using Monoclonal...

A Brief Overview Of Green Biotechnology Tools And Applications

A Brief Overview Of Green...

Key Advantages of Agtech in Farming

Key Advantages of Agtech in Farming

Nanotechnologys Impact on Environment: What to Know

Nanotechnologys Impact on...

How Automation in Pharmaceutical is Giving a New Direction to Drug Development

How Automation in Pharmaceutical is...

Ways Health Economics and Outcomes Research can Improve Decision Making Process

Ways Health Economics and Outcomes...

Top Agtech Industry Trends to Keep an Eye on

Top Agtech Industry Trends to Keep an...

Strategies to Mitigate Life Sciences Supply Chain Challenges

Strategies to Mitigate Life Sciences...

Advantages of Using Monoclonal Antibodies

Advantages of Using Monoclonal...

A Brief Overview Of Green Biotechnology Tools And Applications

A Brief Overview Of Green...

Key Advantages of Agtech in Farming

Key Advantages of Agtech in Farming

Nanotechnologys Impact on Environment: What to Know

Nanotechnologys Impact on...

How Automation in Pharmaceutical is Giving a New Direction to Drug Development

How Automation in Pharmaceutical is...

Ways Health Economics and Outcomes Research can Improve Decision Making Process

Ways Health Economics and Outcomes...

Top Agtech Industry Trends to Keep an Eye on

Top Agtech Industry Trends to Keep an...

Strategies to Mitigate Life Sciences Supply Chain Challenges

Strategies to Mitigate Life Sciences...

How AI Can Enhance the Prediction of Immunotherapy

Jeremy Williams, Life Science Review | Tuesday, February 23, 2021
Tweet

Immunotherapy is using artificial intelligence to predict the progression of the disease with advanced melanoma. 


FREMONT, CA: According to a Cancer Clinical Research study, there is the possibility to predict the outcome of immune checkpoint inhibitors (ICI) therapy by utilizing histology slides and clinical and demographic characteristics of patients. This research aimed to develop a more accessible method for oncologists to identify the reaction to immunotherapy in patients with advanced melanoma.


Many recent studies that show other opportunities for predicting response, but depend on biomarkers, scalability, and demand a considerable amount of resources, are not always plausible. They intend to establish a streamlined process to pre-treatment prognostication by exploiting the available knowledge with the help of routine clinical care.


Two cohort groups were used in the study, the first being a trained group of 121 people who underwent treatment between 2004 and 2018 at New York University. The other cohort is an independent group with 30 patients who received treatment at the University of Vanderbilt.


Researchers created a multivariable classifier that combines clinical data with neutral network predictions, and it was validated on two slide scanners. 


Patients were accurately stratified into the high or low risk of disease development by the classifier. High-risk Vanderbilt patients had worse progression-free survival (PFS) than low-risk ones.


The study also indicated that 50 percent of NYU cohort patients developed disease progression (POD) compared to 64 percent of Vanderbilt cohort patients. A large percentage of the NYU population received monotherapy with anti-CTLA-4, and Vanderbilt patients got anti-PD1-agents.


Researchers have accomplished their hypothesis, and the study shows a suitable method of predicting immunotherapy response. It can be done by incorporating neutral networks classification on histology slides with clinicodemographic information.


With more clinical trials on more extensive databases, the research suggests that the model can be implemented into clinical practice. They note that the shortage of databases is one of the most significant restrictions of this study, and future studies must work on a broader scale.


With such a setting, the quick and readily available method could offer rapid initial assessments to preselect treatment candidates or recognize those who require even more analysis utilizing complementary predictive models.


Weekly Brief

loading
Towards a New World Order
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/how-ai-can-enhance-the-prediction-of-immunotherapy--nwid-264.html